The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of pembrolizumab in combination with cisplatin or carboplatin and etoposide in chemotherapy naive patients with metastatic or unresectable high-grade gastroenteropanncreatic or lung neuroendocrine carcinoma.
 
Robert A. Ramirez
Stock and Other Ownership Interests - Advanced Accelerator Applications (I); Advanced Accelerator Applications (I); Advanced Accelerator Applications (I); Advanced Accelerator Applications (I)
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; bioTheranostics; bioTheranostics; bioTheranostics; bioTheranostics; Novartis; Novartis; Novartis; Novartis
Speakers' Bureau - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck
Research Funding - AADi (Inst); AADi (Inst); AADi (Inst); AADi (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
 
Marc Ryan Matrana
Consulting or Advisory Role - Strata Oncology; Strata Oncology; Strata Oncology; Strata Oncology
Speakers' Bureau - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Genentech; Genentech; Genentech; Genentech; Merck; Merck; Merck; Merck
 
Suma Satti
Speakers' Bureau - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech; Genentech; Genentech; Genentech; Merck; Merck; Merck; Merck
 
Ryan Patrick Griffin
No Relationships to Disclose
 
Brianne A Voros
No Relationships to Disclose
 
Yvette Bren-Mattison
No Relationships to Disclose